Bisphosphonates in prostate carcinoma

Cancer

Volumn 80, Issue 8 SUPPL., 1997, Pages 1674-1679

  Adami, Silvano ^a,b  

^a UNIVERSITY OF VERONA   (Italy)

^b Ospedale di Valeggio   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; ETIDRONIC ACID;

BONE METASTASIS; BONE PAIN; CANCER PAIN; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PAIN ASSESSMENT; PRIORITY JOURNAL; PROSTATE CARCINOMA; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME;

EID: 0030844752     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0142(19971015)80:8+<1674::aid-cncr18>3.0.co;2-x     Document Type: Conference Paper

References (48)

1. Abrams HL, Spiro R, Goldstein N. Metastases in carcinomas: analysis of 1000 autopsied cases. Cancer 1950;3:74-85.
2. Galasko CSB. Mechanism of lytic and blastic metastatic disease of bone. Clin Orthop 1982; 12:20-7.
3. Geller J. Overview of enzyme inhibitors and anti-androgens in prostatic cancer. J Androl 1991: 12:364-71.
4. Flanagan AM, Chambers TJ. Clodronate inhibits resorption through injury of osteoclast that resorbs clodronate coated bone. Bone Miner 1989:6:33-43.
5. Löwik CWGM, van der Pluijm G, Bijvoet OLM. Migration and phenotypic transformation of osteoclast precursors into mature osteoclasts, the effects of a bisphosphonate. J Bone Miner Res 1988;3:185-92.
6. Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman GD, et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 1995; 10: 1478-87.
7. Rogers MJ, Watts DJ, Russell RGG, Ji X, Xiong X, Blackburn GM, et al. Inhibitory effects of bisphosphonates on growth of amebae of the cellular slime mold dictostelium discoideum. J Bone Miner Res 1994;9:1029-39.
8. van der Pluijm G, Vloedgraven H, van Beek E, van der Wee-Pals L, Löwik C, Papapoulos S. Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest 1996;98:698-705.
9. Paterson AHG, Powels TJ, Kanis JA, McCloskey E, Hanson J, Ashley S. Double-blind controlled trial of clodronate in patients with bone metastases from breast cancer. J Clin Oncol 1993;11:59-65.
10. Lahtinen R, Laasko M, Palva I, Virkkuen P, Elomaa I, for the Finnish Leukaemia Group. Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Lancet 1992;340:1049.
11. Kanis JA, Poweles T, Paterson AHG, McCloskey EV, Ashley S. Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone 1996;19:663-7.
12. Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 1996;334:488-93.
13. Conte PF, Giannessi PG, Latreille J, Mauriac L, Koliren L, Calabresi F, et al. Delayed progression of bone metastases with pamidronate therapy in breast cancer patients: a randomised, multicenter phase III trial. Ann Oncol 1994;5(Suppl 7):S41-4.
14. Adami S, Salvagno G, Guarrera G, Bianchi G, Dorizzi R, Rosini S, et al. Dichloromethylene-disphosphonate in patients with prostatic carcinoma metastatic to the skeleton. J Urol 1985;134:1152-4.
15. Adami S, Mian M. Clodronate therapy of metastatic bone disease in patients with prostatic carcinoma. Recent Results Cancer Res 1989; 116:67-72.
16. Clarke NW, McClure J, George NJR. Clinical and metabolic effects of disodium pamidronate in metastatic prostate cancer. In: Bijvoet OLM, Lipton A, editors. Osteoclastic inhibition in the menagement of malignancy-related bone disorders. Toronto: Hogrefe and Huber Publishers, 1991:54-63.
17. Carey PO, Lippert MC. The treatment of painful prostatic bone metastases with oral etidronate sodium. Urology 1988; 32:403-7.
18. Clarke NW, McClure J, George NJR. Subjective and metabolic affects of aminohydroxypropylidene bisphosphonate (APD) in patients with advanced cancer of the prostate: preliminary report. In: Rubens RD, editor. The menagement of bone metastases and hypercalcemia by osteoclast inhibition. Toronto: Hogrefe and Huber Publishers, 1990:81-9.
19. Masud T, Slevin ML. Pamidronate to reduce pain in normocalcemic patients with disseminated prostatic carcinoma. Lancet 1989;1:1021-2.
20. Lipton A, Grabelsky S, Glover D, Harvey H, Simeone J, Seaman S. Pamidronate disodium (APD): the American experience in breast and prostate cancer. Bone Miner 1992;17(Suppl 1):S27.
21. Percival RC, Watson ME, Williams JL, Kanis JA. Carcinoma of the prostate: remission of paraparesis with inhibitors of bone resorption. Postgrad Med J 1985;61:551-3.
22. Scher HI, Yagoda A. Bone metastases: pathogenesis, treatment and rationale for use of resorption inhibitors. Am J Med 1987;82(Suppl 2A):6-28.
23. Kylmälä T, Tammela TLJ, Risteli L, Risteli J, Taube T, Elomaa I. Evaluation of the effect of oral clodronate on skeletal metastases with type 1 collagen metabolites. A controlled trial of the Finnish prostate cancer group. Eur J Cancer 1993; 29A:821-5.
24. Purohit OP, Anthony C, Radstone CR, Owen J, Coleman RE. High-dose intravenous pamidronate for metastatic bone pain. Br J Cancer 1994;70:554-8.
25. Kylmälä T, Tammela TLJ, Lindholm TS, Seppänen J. The effect of combined intravenous and oral clodronate treatment on bone pain in patients with metastatic prostate cancer. Ann Chir Gynaecol 1994;83:316-9.
26. Elomaa I, Kylmälä T, Tammela TLJ, Lindholm TS, Risteli L, et al. Effect of clodronate on bone pain. A controlled study in patients with metastatic prostate cancer. Int Urol Nephrol 1992;24:159-61.
27. Schnur W. Etidronate for the relief of metastatic bone pain. J Urol 1984;131:404-7.
28. Hosking DJ, Chamberlain MJ, Shortland-Webb WR. Osteomalacia and carcinoma of the prostate with major re-distribution of skeletal calcium. Br J Radiol 1975;48:451-6.
29. Simpson E, Harrod J, Eilon G, Jacobson JW, Mundy GR. Identification of a messenger ribonucleic acid fraction in human prostatic cancer cells coding for a novel osteoblast-stimulating factor. Endocrinology 1985;117:1615-20.
30. Koutsilieris M, Rabbani SA, Bennet HP, Goltzman D. Characteristics of prostate-derived growth factors for cells of the osteoblast phenotype. J Clin Invest 1987;80:941-6.
31. Rabbani SA, Desjardins J, Bell AW, Banville D, Mazar A, Goltzman D. An aminoterminal fragment of urokinase isolated from a prostate cancer cell line (PC-3) is mitogenic for osteoblast-like cells. Biochem Biophys Res Commun 1990; 173:1058-64.
32. Percival RC, Urwin GH, Watson ME, McClosky M, Kanis JA, et al. Biochemical and histological evidence that carcinoma of the prostate is associated with increased bone resorption. Eur J Surg Oncol 1987;13:41-9.
33. Vinholes J, Guo CY, Purohit OP, Eastell R, Coleman RE. Metabolic effects of pamidronate in patients with metastatic bone disease. Br J Cancer 1996;73:1089-95.
34. Coleman RE, Houston S, James I, Rodger A, Rubens RD, Leonard RCF, et al. Preliminary results of the use of urinary excretion of pyridinium cross-links for monitoring metastatic bone disease. Br J Cancer 1992;65:766-8.
35. Lipton A, Demers L, Daniloff Y, Curley E, Hamilton C, Harvey H, et al. Increased urinary excretion of pyridinium cross-links in cancer patients. Clin Chem 1993;39:614-8.
36. Pecherstorfer M, Ludwig H, Zimmer-Roth H, Schiling T, Woitge HW, Schmidt H, et al. The diagnostic value of urinary pyridinium cross-links of collage, alkaline phosphatase and urinary calcium excretion in neoplastic bone disease. J Clin Endocrinol Metab 1995;80:97-103.
37. Koizumi M, Yamada Y, Takiguchi T, Nomura E, Furukawa M, Kitahara T, et al. Bone metabolic markers in bone metastases. J Cancer Res Clin Oncol 1995;121:542-8.
38. Urwin GH, Percival RC, Harris S, Beneton MNC, Williams JL, Kanis SA. Generalized increase in bone resorption in carcinoma of the prostate. Eur J Urol 1985;57:721-3.
39. Clarke NW, McClure J, George NJR. Morphometric evidence for bone resorption and replacement in prostate cancer. Br J Urol 1991;68:74-80.
40. Li F, Pitt PI, Sherwood R, Barrett J, Houghton J, Parsons V, et al. Biochemical markers of bone turnover in women with surgically treated carcinoma of the breast. Eur J Clin Invest 1992;23:566-71.
41. Smith JA. Palliation of painful bone metastases from prostate cancer using sodium etidronate: results of a randomized, prospective, double-blind, placebo-controlled study. J Urol 1989;141:85-7.
42. Pelger RCM, Lycklama A, Nijeholt AAB, Papapoulos SE. Short-term metabolic effects of pamidronate in patients with prostatic carcinoma and bone metastases. Lancet 1989;2:865.
43. Bishop M, Fellows G. Urinary hydroxyproline excretion-a marker of bone metastases in prostatic carcinoma. Br J Urol 1977;49:711-8.
44. Adami S, Frijlink WB, Bijvoet OLM, O'Riordan JLH, Clemens TL, Papapoulos SE. Regulation of calcium absorption by 1,25,dihydroxy-vitamin D. Studies of the effects of a bisphosphonare treatment. Calcif Tissue Int 1982;34:317-20.
45. Thiebaud D, Leyvraz S, von Fliedner V, Percy L, Burckardt P. Treatment of bone metastases from breast cancer and myeloma with pamidronate. Eur J Cancer 1991;27:37-41.
46. Lipton A, Glover D, Harvey H, Grabelsky S, Zelenakas K, Macerta R, et al. Pamidronate in the treatment of bone metastases: results of 2 dose-ranging trials in patients with breast or prostate cancer. Ann Oncol 1994;5(Suppl 7):31-5.
47. Pecherstorfer M, Schiling T, Janisch S, Woloszczuk W, Baumgartner G, Ziegler R, et al. Effect of clodronate treatment on bone scintigraphy in metastatic breast cancer. J Nucl Med 1993;34:1039-44.
48. Adami S. Bisphosphonates and prostatic carcinoma with bone metastases. In: Bijvoet OLM, Fleisch HA, Canfield RE, Russell RGG, editors. Bisphosphonate on bones. Amsterdam: Elsevier, 1995:380-4.